June 10 Shares plunged after news broke that a panel of outside advisors to the FDA recommended approving Praluent, the company's new cholesterol-lowering medication. What shook investors was the vote tally, with 13 on the panel voting in favor but three voting against. The reason given for the three negative votes was the lack of long-term outcomes data for the drug. Specifically, some panel members openly questioned the idea that lowering LDL cholesterol would lead to a lower risk of cardiovascular disease. Regeneron and its partner, Sanofi, are currently running long-term trials to test Praluent's ability to lower the risk of cardiovascular disease, but those results won't be on hand until 2017.